From Medscape Dermatology

Coverage from the

European Academy of Dermatology and Venereology (EADV) 2023 Congress

October 11 - 14, 2023; Berlin, Germany

October 11 - 14, 2023 Berlin, Germany

EADV 2023 Vitiligo: 'Impressive' Results for Povorcitinib, Baricitinib Substantial facial and total body repigmentation in patients with nonsegmental vitiligo was achieved in separate trials of povorcitinib and baricitinib plus phototherapy.
Medscape Medical News, November 8, 2023
EADV 2023 Nemolizumab Promise for Prurigo Nodularis Continues Results from OLYMPIA 1 provide further support for nemolizumab as a potential first-in-class prurigo nodularis treatment; in another study, a JAK inhibitor was beneficial in patients with PN.
Medscape Medical News, October 25, 2023

Conference News

EADV 2023 Novel Subcutaneous Biologics Show Promise in AD
Medscape Medical News, December 1, 2023
Tapinarof Effective for AD in Patients as Young as 2 years
MDedge News, November 28, 2023
HS: Positive Results Reported With Anti-IL17A/F Therapies
MDedge News, November 28, 2023
EADV 2023 At 52 Weeks, Hair Growth Still Climbing on Deuruxolitinib
MDedge News, November 28, 2023
EADV 2023 BDD: Diagnosis Guidelines to be Published in Europe
MDedge News, November 8, 2023
EADV 2023 Vitiligo: 'Impressive' Results for Povorcitinib, Baricitinib
Medscape Medical News, November 8, 2023
EADV 2023 Topical Ivermectin Study Sheds Light on Dysbiosis in Rosacea
Medscape Medical News, November 3, 2023

EADV 2023 Study Finds Ruxolitinib Effective, Safe for Children With AD
MDedge News, November 1, 2023
EADV 2023 Nemolizumab Promise for Prurigo Nodularis Continues
Medscape Medical News, October 25, 2023
EADV 2023 Oleogel-S10 Reduces Daily Dressing Need in EB Study
Medscape Medical News, October 24, 2023
EADV 2023 AI Can Flag Skin Cancer With Near-Perfect Accuracy
Medscape Medical News, October 20, 2023
EADV 2023 Recombinant IL-2 Shows Potential in Atopic Dermatitis
Medscape Medical News, October 18, 2023
EADV 2023 Patients With Psoriasis Lose Weight With Roflumilast: Study
Medscape Medical News, October 13, 2023
EADV 2023 Topical Botanical Drug Coacillium Curbs Childhood Alopecia
Medscape Medical News, October 12, 2023

Medscape Dermatology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Popular News From EADV 2022

Hope Shines Bright for Hidradenitis Suppurativa Treatments Secukinumab and the investigational drug brepocitinib were shown to alleviate the effects of the chronic and painful skin condition in separate, unrelated trials.
Medscape Medical News, Sep 16, 2022
Study Identifies Skin Biomarkers That Predict Newborn Eczema Risk During the first 2 months of life, changes in skin biomarkers were predictive of whether children would develop atopic dermatitis up to 2 years later.
Medscape Medical News, Sep 28, 2022
Anti-IgE Therapy Found Safe and Effective for Chronic Urticaria Both doses of ligelizumab evaluated met the primary endpoint of superiority to placebo for a complete response at 16 weeks of therapy.
Medscape Medical News, Sep 15, 2022

Previous Coverage

Related Resources